Mostra i principali dati dell'item
DNA methylation analysis in plasma cell-free DNA and paired CTCs of NSCLC patients before and after osimertinib treatment
dc.creator | Ntzifa A., Londra D., Rampias T., Kotsakis A., Georgoulias V., Lianidou E. | en |
dc.date.accessioned | 2023-01-31T09:40:58Z | |
dc.date.available | 2023-01-31T09:40:58Z | |
dc.date.issued | 2021 | |
dc.identifier | 10.3390/cancers13235974 | |
dc.identifier.issn | 20726694 | |
dc.identifier.uri | http://hdl.handle.net/11615/77365 | |
dc.description.abstract | Osimertinib has been an effective second-line treatment in EGFR mutant NSCLC patients; however, resistance inevitably occurs. DNA methylation has been previously implicated in NSCLC progression and often in therapy resistance, however its distinct role in osimertinib resistance is not elucidated as yet. In the present study, we directly compared DNA methylation of nine selected genes (RASSF1A, RASSF10, APC, WIF-1, BRMS1, SLFN11, RARβ, SHISA3, and FOXA1) in plasma-cfDNA and paired CTCs of NSCLC patients who were longitudinally monitored during osimertinib treatment. Peripheral blood (PB) from 42 NSCLC patients was obtained at two time points: (a) baseline: before treatment with osimertinib and (b) at progression of disease (PD). DNA methylation of the selected genes was detected in plasma-cfDNA (n = 80) and in paired CTCs (n = 74). Direct comparison of DNA methylation of six genes between plasma-cfDNA and paired CTC samples (n = 70) revealed a low concordance, indicating that CTCs and cfDNA give complementary information. DNA methylation analysis of plasma-cfDNA and CTCs indicated that when at least one of these genes was methylated there was a statistically significant increase at PD compared to baseline (p = 0.031). For the first time, DNA methylation analysis in plasma-cfDNA and paired CTCs of NSCLC patients during osimertinib therapy indicated that DNA methylation of these genes could be a possible resistance mechanism. © 2021 by the authors. Licensee MDPI, Basel, Switzerland. | en |
dc.language.iso | en | en |
dc.source | Cancers | en |
dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85119991395&doi=10.3390%2fcancers13235974&partnerID=40&md5=49b72be86df064680bc329c69a269aea | |
dc.subject | APC protein | en |
dc.subject | DNA | en |
dc.subject | hepatocyte nuclear factor 3alpha | en |
dc.subject | osimertinib | en |
dc.subject | Ras association domain family protein 1A | en |
dc.subject | adult | en |
dc.subject | aged | en |
dc.subject | Article | en |
dc.subject | blood sampling | en |
dc.subject | BRMS1 gene | en |
dc.subject | cancer growth | en |
dc.subject | cancer patient | en |
dc.subject | cancer resistance | en |
dc.subject | circulating tumor cell | en |
dc.subject | clinical article | en |
dc.subject | DNA methylation | en |
dc.subject | epigenetics | en |
dc.subject | female | en |
dc.subject | follow up | en |
dc.subject | FOXA1 gene | en |
dc.subject | gene | en |
dc.subject | human | en |
dc.subject | human tissue | en |
dc.subject | liquid biopsy | en |
dc.subject | longitudinal study | en |
dc.subject | male | en |
dc.subject | non small cell lung cancer | en |
dc.subject | plasma cell | en |
dc.subject | plasma cell free DNA | en |
dc.subject | RAR beta gene | en |
dc.subject | RASSF10 gene | en |
dc.subject | RASSF1A gene | en |
dc.subject | SHISA3 gene | en |
dc.subject | SLFN11 gene | en |
dc.subject | very elderly | en |
dc.subject | WIF 1 gene | en |
dc.subject | MDPI | en |
dc.title | DNA methylation analysis in plasma cell-free DNA and paired CTCs of NSCLC patients before and after osimertinib treatment | en |
dc.type | journalArticle | en |
Files in questo item
Files | Dimensione | Formato | Mostra |
---|---|---|---|
Nessun files in questo item. |